28 Dalgleish Street
GroPep Limited is a biopharmaceutical company that develops, manufactures and commercialises products that bring significant benefits to human health. GroPep listed on the Australian Stock Exchange in 2000. Our 80 staff are based at modern, purpose built facilities in Adelaide, South Australia.
The Company is a globally orientated business with exports contributing 95% of sales revenue and 72% of total revenue. GroPep operates two related business activities:
1) Biopharmaceutical Drug Development
GroPep's strategy is to in-license preclinical projects and develop them from pre-clinical proof-of-concept through phase 2 trials. During clinical development, GroPep will partner with branded pharmaceutical companies to complete clinical development. Currently there are 5 products in clinical development, 4 of which are available for licensing.
GroPep is currently seeking new in-licensing opportunities to maintain its pipeline. Our core technical competencies are:
Development of processes for GMP implementation
Clinical trials design and management
We have extensive know how, capabilities and experience in these areas which are critical to successful biopharmaceutical drug development.
2) Biological Products
GroPep develops, manufactures and markets growth factors for use in pharmaceutical cell culture. Our leading product, LongTMR3IGF-I, is marketed and distributed by JRH Biosciences Inc, a subsidiary of CSL Limited. Three US FDA approved pharmaceuticals are manufactured using GroPep growth factors, with a number of other potential pharmaceuticals in development using GroPep growth factors. GroPep also sells growth factors and associated reagents to university, institutional and industrial researchers.
Total revenue of $10.8 million, 6.6% higher than 2001-02
Product sales revenue of $7.2 million, 3.8% higher than 2001-02
Completed Phase 1b clinical trial of PV701 for oral mucositis
Completed patient recruitment for the Phase 2 trial of PV702, a treatment for chronic venous ulcers
PP9903, GroPep's drug candidate for recurrent miscarriage, is scheduled to begin Phase I clinical trials in mid 2004
Last Updated: 05-27-04